Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis

Journal of Hepatology

Volumn 38, Issue 6, 2003, Pages 717-727

  Zollner, Gernot ^a   Fickert, Peter ^a   Silbert, Dagmar ^a   Fuchsbichler, Andrea ^a   Marschall, Hanns Ulrich ^b   Zatloukal, Kurt ^a   Denk, Helmut ^a   Trauner, Michael ^a  

^a UNIVERSITY OF GRAZ   (Austria)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Bile salts; Bilirubin; Cholestasis; Transport; Ursodeoxycholic acid

Indexed keywords

BILE ACID; BILE SALT; BILE SALT EXPORT PUMP; CARRIER PROTEIN; DIPEPTIDYL PEPTIDASE IV; MESSENGER RNA; ORGANIC ANION TRANSPORTER; PHOSPHOLIPID; SODIUM TAUROCHOLATE COTRANSPORTER; TAUROCHOLIC ACID; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

ADAPTATION; ADULT; ARTICLE; BILIARY CIRRHOSIS; CHOLESTASIS; CONTROLLED STUDY; FEMALE; HEPATOBILIARY SYSTEM; HUMAN; HUMAN TISSUE; HYDROPHOBICITY; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; INTRAHEPATIC BILE DUCT; MALE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 0013138711     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(03)00096-5     Document Type: Article

References (51)

1. Kullak-Ublick GA, Beuers U, Paumgartner G. Hepatobiliary transport. J Hepatol 2000;32:3-18.
2. Trauner M, Meier PJ, Boyer JL. Molecular pathogenesis of cholestasis. N Engl J Med 1998;339:1217-1227.
3. Lee J, Boyer JL. Molecular alterations in hepatocyte transport mechanisms in acquired cholestatic liver disorders. Semin Liver Dis 2000;20:373-384.
4. Kullak-Ublick GA, Meier PJ. Mechanisms of cholestasis. Clin Liver Dis 2000;4:357-385.
5. Zollner G, Fickert P, Zenz R, Fuchsbichler A, Stumptner C, Kenner L, et al. Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. Hepatology 2001;33:633-646.
6. Shoda J, Kano M, Oda K, Kamiya J, Nimura Y, Suzuki H, et al. The expression levels of plasma membrane transporters in the cholestatic liver of patients undergoing biliary drainage and their association with the impairment of biliary secretory function. Am J Gastroenterol 2001;96:3368-3378.
7. Oswald M, Kullak-Ublick GA, Paumgartner G, Beuers U. Expression of hepatic transporters OATP-C and MRP2 in primary sclerosing cholangitis. Liver 2001;21:247-253.
8. Kullak-Ublick GA, Baretton GB, Oswald M, Renner EL, Paumgartner G, Beuers U. Expression of the hepatocyte canalicular multidrug resistance protein (MRP2) in primary biliary cirrhosis. Hepatol Res 2002;23:78-82.
9. Schrenk D, Gant TW, Preisegger KH, Silverman JA, Marino PA, Thorgeirsson SS. Induction of multidrug resistance gene expression during cholestasis in rats and non-human primates. Hepatology 1993;17:854-860.
10. Donner MG, Keppler D. Up-regulation of basolateral multidrug resistance protein 3 (Mrp3) in cholestatic rat liver. Hepatology 2001;34:351-359.
11. Soroka CJ, Lee JM, Azzaroli F, Boyer JL. Cellular localization and up-regulation of multidrug resistance-associated protein 3 in hepatocytes and cholangiocytes during obstructive cholestasis in rat liver. Hepatology 2001;33:783-791.
12. Lee JM, Trauner M, Soroka CJ, Stieger B, Meier PJ, Boyer JL. Expression of the bile salt export pump is maintained after chronic cholestasis in the rat. Gastroenterology 2000;118:163-172.
13. +/bile acid cotransporter in extrahepatic cholestasis. Gastroenterology 1996;110:199-209.
14. Lee J, Azzaroli F, Wang L, Soroka CJ, Gigliozzi A, Setchell KD, et al. Adaptive regulation of bile salt transporters in kidney and liver in obstructive cholestasis in the rat. Gastroenterology 2001;121:1473-1484.
15. Heathcote EJ. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology 2000;31:1005-1013.
16. Poupon R, Chazouilleres O, Poupon RE. Chronic cholestatic diseases. J Hepatol 2000;32:129-140.
17. Trauner M, Graziadei IW. Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases. Aliment Pharmacol Ther 1999;13:979-996.
18. Hofmann AF. The continuing importance of bile acids in liver and intestinal disease. Arch Intern Med 1999;159:2647-2658.
19. Fickert P, Zollner G, Fuchsbichler A, Stumptner C, Pojer C, Zenz R, et al. Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver. Gastroenterology 2001;121:170-183.
20. Ludwig J, Dickson ER, McDonald GS. Staging of chronic non-suppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol 1978;379:103-112.
21. Setchell KD, Rodrigues CM, Clerici C, Solinas A, Morelli A, Gartung C, et al. Bile acid concentrations in human and rat liver tissue and in hepatocyte nuclei. Gastroenterology 1997;112:226-235.
22. Marschall HU, Broome U, Einarsson C, Alvelius G, Thomas HG, Matern S. Isoursodeoxycholic acid: metabolism and therapeutic effects in primary biliary cirrhosis. J Lipid Res 2001;42:735-742.
23. Krieg P, Amtmann E, Sauer G. The simultaneous extraction of high-molecular-weight DNA and of RNA from solid tumors. Anal Biochem 1983;134:288-294.
24. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-685.
25. Roman LM, Hubbard AL. A domain-specific marker for the hepatocyte plasma membrane: localization of leucine aminopeptidase to the bile canalicular domain. J Cell Biol 1983;96:1548-1558.
26. Kubitz R, Wettstein M, Warskulat U, Haussinger D. Regulation of the multidrug resistance protein 2 in the rat liver by lipopolysaccharide and dexamethasone. Gastroenterology 1999;116:401-410.
27. Zollner G, Fickert P, Silbert D, Fuchsbichler A, Stumptner C, Zatloukal K, et al. Induction of short heterodimer partner 1 precedes down-regulation of Ntcp in bile duct-ligated mice. Am J Physiol Gastrointest Liver Physiol 2002;282:G184-G191.
28. Lotterer E, Stiehl A, Raedsch R, Foelsch UR, Bircher J. Ursodeoxycholic acid in primary biliary cirrhosis: no evidence for toxicity in the stages I-III. J Hepatol 1990;10:284-290.
29. Dusol Jr M, Schiff ER. Clinical approach to jaundice. Postgrad Med 1975;57:118-124.
30. Hirohashi T, Suzuki H, Takikawa H, Sugiyama Y. ATP-dependent transport of bile salts by rat multidrug resistance-associated protein 3 (Mrp3). J Biol Chem 2000;275:2905-2910.
31. Akita H, Suzuki H, Hirohashi T, Takikawa H, Sugiyama Y. Transport activity of human MRP3 expressed in Sf9 cells: comparative studies with rat MRP3. Pharm Res 2002;19:34-41.
32. Gerber MA, Orr W, Denk H, Schaffner F, Popper H. Hepatocellular hyalin in cholestasis and cirrhosis: its diagnostic significance. Gastroenterology 1973;64:89-98.
33. Raedsch R, Lauterburg BH, Hofmann AF. Altered bile acid metabolism in primary biliary cirrhosis. Dig Dis Sci 1981;26:394-401.
34. Batta AK, Arora R, Salen G, Tint GS, Eskreis D, Katz S. Characterization of serum and urinary bile acids in patients with primary biliary cirrhosis by gas-liquid chromatography-mass spectrometry: effect of ursodeoxycholic acid treatment. J Lipid Res 1989;30:1953-1962.
35. Jansen PL, Strautnieks SS, Jacquemin E, Hadchouel M, Sokal EM, Hooiveld GJ, et al. Hepatocanalicular bile salt export pump deficiency in patients with progressive familial intrahepatic cholestasis. Gastroenterology 1999;117:1370-1379.
36. Sakisaka S, Kawaguchi T, Taniguchi E, Hanada S, Sasatomi K, Koga H, et al. Alterations in tight junctions differ between primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology 2001;33:1460-1468.
37. Vos TA, Hooiveld GJ, Koning H, Childs S, Meijer DK, Moshage H, et al. Up-regulation of the multidrug resistance genes, Mrp1 and Mdr1b, and down-regulation of the organic anion transporter, Mrp2, and the bile salt transporter, Spgp, in endotoxemic rat liver. Hepatology 1998;28:1637-1644.
38. Trauner M, Arrese M, Soroka CJ, Ananthanarayanan M, Koeppel TA, Schlosser SF, et al. The rat canalicular conjugate export pump (Mrp2) is down-regulated in intrahepatic and obstructive cholestasis. Gastroenterology 1997;113:255-264.
39. Ros JE, Schuetz JD, Geuken M, Streetz K, Moshage H, Kuipers F, et al. Induction of Mdr1b expression by tumor necrosis factor-alpha in rat liver cells is independent of p53 but requires NF-kappaB signaling. Hepatology 2001;33:1425-1431.
40. Mauad TH, Van Nieuwkerk CM, Dingemans KP, Smit JJ, Schinkel AH, Notenboom RG, et al. Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of non-suppurative inflammatory cholangitis and hepatocarcinogenesis. Am J Pathol 1994;145:1237-1245.
41. Fickert P, Zollner G, Fuchsbichler A, Stumptner C, Weiglein AH, Lammert F, et al. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology 2002;123:1238-1251.
42. Jacquemin E. Role of multidrug resistance three deficiency in pediatric and adult liver disease: one gene for three diseases. Semin Liver Dis 2001;21:551-562.
43. de Vree JM, Jacquemin E, Sturm E, Cresteil D, Bosma PJ, Aten J, et al. Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis. Proc Natl Acad Sci USA 1998;95:282-287.
44. Dumoulin FL, Reichel C, Sauerbruch T, Spengler U. Semiquantitation of intrahepatic MDR3 mRNA levels by reverse transcription/competitive polymerase chain reaction. J Hepatol 1997;26:852-856.
45. Asamoto Y, Tazuma S, Ochi H, Chayama K, Suzuki H. Bile-salt hydrophobicity is a key factor regulating rat liver plasma-membrane communication: relation to bilayer structure, fluidity and transporter expression and function. Biochem J 2001;359:605-610.
46. Prieto J, Qian C, Garcia N, Diez J, Medina JF. Abnormal expression of anion exchanger genes in primary biliary cirrhosis. Gastroenterology 1993;105:572-578.
47. Medina JF, Martinez A, Vazquez JJ, Prieto J. Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis. Hepatology 1997;25:12-17.
48. Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 2002;36:525-531.
49. Guo GL, Staudinger J, Ogura K, Klaassen CD. Induction of rat organic anion transporting polypeptide 2 by pregnenolone-16alpha-carbonitrile is via interaction with pregnane X receptor. Mol Pharmacol 2002;61:832-839.
50. Kast HR, Goodwin B, Tarr PT, Jones SA, Anisfeld AM, Stoltz CM, et al. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem 2002;277:2908-2915.
51. Schuetz EG, Strom S, Yasuda K, Lecureur V, Assem M, Brimer C, et al. Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450. J Biol Chem 2001;276:39411-39418.